抄録
The development of a prophylactic and therapeutic vaccine against human herpesvirus infection represents the best hope for controlling the continuing and devastating worldwide herpes endemic. A successful preventative herpesvirus vaccine need to induce both systemic and mucosal protective immunity. We previously described the possibility of oral immunization with live HSV-1 as a vaccine and presented evidence suggesting that the best immunization method for preventing this viral infection is the oral route rather than other routes such as cutaneous or intravenous ones. Oral administration induces the and-HSV-1 antibody on the mucosal surfaces where most viruses enter the body and provides systemic immunity. Further work is required to establish optimal immunization conditions and to explore the use of safer immunogens. We outline here the future plans for developing the oral engineering of recombinant live vectors such as vaccinia expressing the combination of two or more epitopes that induce excellent cellular and humoral immunity against acute and latent herpesvirus infection.
